Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by lonc17on Dec 15, 2023 2:58pm
258 Views
Post# 35787269

Fair Market Value

Fair Market ValueMC very likely has not exercised his options with a strike price of $1.45

If he did this on December 13th, then he would have five days to report the transaction. Techincally he could have till mid-week next week to report, but there would be no reason to wait and it would almost certainly have been reported by now had it actually occured.

This is important to note for all current and prospective shareholders of ONC.

Matt Coffey, the CEO of Oncolytics Biotech has let everyone know that by his own analysis, the current fair market value of ONC is less than $1.45 CDN. He's also strongly suggesting by his lack of action that the potential for any major postive news in the next one to two years is exceptionally low.

I'll update this if I see anything different on SEDI, but why the hell anyone would buy at a price over $1.45 when ONC's own CEO refuses the option to buy at $1.45 is beyond me.

A CEO who for all intents and purposes refuses to own more than a token stake in his company is a useless twit in my opinion.



<< Previous
Bullboard Posts
Next >>